Mickle Travis C's Form 4 filing
Zevra Therapeutics, Inc. (ZVRA) · filed Nov 23, 2021
- Accession no.
- 0001437749-21-027301
- Filed
- Nov 23, 2021
- Trade date
- Nov 18, 2021
- Filing delay
- 5 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction. Open-market purchases total $18.5K. It was filed 5 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Mickle Travis CCIK 0001638365 | Director, Officer (President & CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 18, 2021 | Common Stock | PPurchaseAcquired | +2,250 | $8.23 | +$18,517.5 | 36,521 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.